肽受体放射性核素治疗作为晚期不可手术/转移性神经内分泌肿瘤一线全身治疗
PURPOSE: Advanced inoperable/metastatic neuroendocrine tumors (NETs) pose a therapeutic challenge with limited treatment options.…
要点
- 40例可评估患者中部分缓解30%、疾病稳定55%、进展15%。
- 3/4级贫血、白细胞减少、中性粒细胞减少及肝毒性分别为2%、2%、4%、4%。
核心结论
- 一线PRRT在晚期不可手术/转移性NET中显示有效且安全。
- 需未来随机试验比较PRRT与生长抑素类似物以确定治疗顺序。
研究设计与样本
- 40例可评估影像学反应(3例失访,2例CT病灶不可测量),采用RECIST 1.1标准评估。
主要发现
- 40例可评估患者中12例(30%)达部分缓解,22例(55%)疾病稳定,6例(15%)疾病进展。
- 中位无进展生存期为48个月(95%CI 34.7-61.3个月)。
- 3/4级贫血、白细胞减少、中性粒细胞减少及肝毒性发生率分别为2%、2%、4%、4%。
关键数值与推荐
- 放射学反应采用RECIST 1.1标准评估。
- 卡培他滨剂量为1250 mg/m²,每周期第0-14天给药。
- 3/4级不良事件:贫血2%、白细胞减少2%、中性粒细胞减少4%、肝毒性4%。
- 中位无进展生存期48个月(95%CI 34.7-61.3个月)。
临床怎么用
- 治疗期间需监测血液学及肝脏毒性,3/4级不良事件发生率较低。
局限性
- 缺乏与生长抑素类似物等标准一线治疗的随机对照比较。
- 部分患者(5例)因失访或病灶不可测量未能纳入影像学反应评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Advanced inoperable/metastatic neuroendocrine tumors (NETs) pose a therapeutic challenge with limited treatment options. Peptide receptor radionuclide therapy (PRRT), being specific in targeting the somatostatin receptors, is a promising and viable option in this setting. In this study, we intended to evaluate the role of PRRT as the first-line systemic therapy in advanced inoperable/metastatic NETs. METHODS: Data of consecutive patients of advanced inoperable/metastatic NETs treated with first-line Lu-DOTATATE at our center, from September 2012 to August 2019, were collected and analyzed. RESULTS: Forty-five patients (median age, 50 years; range, 14-72 years) with treatment-naive advanced NETs received a median cumulative dose of 27 GBq (range, 13.3-41.3 GBq; over 2-7 cycles) Lu-DOTATATE and 1250 mg/m capecitabine from days 0 to 14 of each PRRT cycle. Three patients were lost to follow-up, 2 had nonmeasurable lesions on CT, and hence, radiological response using Response Evaluation Criteria in Solid Tumors version 1.1 could be assessed in 40 patients. Twelve of 40 patients (30%) showed a partial response, whereas stable disease was observed in 22 of 40 patients (55%). Disease progression was limited to 6 of 40 patients (15%). Treatment-related adverse effects were minimal with grade 3/4 anemia, leukopenia, neutropenia, and hepatotoxicity observed in 2%, 2%, 4%, and 4% of the patients, respectively. Median progression-free survival was 48 months (95% confidence interval, 34.7-61.3 months). CONCLUSIONS: Our results indicate the efficacy and safety of first-line PRRT in advanced NETs. Future randomized trials, comparing PRRT and somatostatin analogs in treatment-naive patients, are required to identify the definite sequence of treatment options for these patients.
引用
- Satapathy S, Mittal BR, Sood A, et al. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors. Clin Nucl Med. 2020. PMID: 32604121. doi:10.1097/RLU.0000000000003170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。